Drug and device promotion has traditionally been regulated according to the content of a communication, rather than the medium used to deliver it. Draft guidance on social media promotion issued in 2014 addressed how those rules applied to platforms with little space for a complete message. A character limit did not eliminate the obligation to provide information required to support a promotional claim.
The guidance dealt with two related questions. One involved the presentation of benefit and risk information in communications with limited space. The other involved companies that wanted to correct misinformation posted by independent users. The guidance treated both questions as applications of existing promotional expectations. It did not treat social media as an exception simply because messages on those platforms are short.
Benefit and risk information
A promotional communication that names a product and makes a claim about it must present risk information with that claim. The risk information must appear in the same message. A separate page reached through a link cannot replace that initial disclosure. The agency also expected the short communication to include a link to a fuller statement of risk.
That structure created difficulties for products with lengthy safety information. A company could not devote the available space to a benefit claim and move the safety discussion to another page. The message had to contain the claim and related risk information, then provide a route to more complete information.
The relevant question was the content of the communication, not just the platform where it appeared. A short post making a product claim would be assessed based on what it said and whether the required risk information appeared alongside the claim. The draft guidance applied existing expectations to a restricted format. It did not create a separate standard for promotion on social media.
Correcting misinformation
The second question concerned statements posted by independent users. A manufacturer generally is not responsible for statements that independent users make about its products. Companies still questioned whether a voluntary correction could make them responsible for an entire page or discussion.
The draft guidance took a narrow view of such corrections. The response had to be truthful and non-promotional. It also had to address only the specific misinformation and clearly identify the company as the source. Under those conditions, a company could respond to a particular false statement without turning the response into a wider product message.
The correction had to stay focused on the inaccurate content. A company could not use the response to add general promotional material. This distinction allowed a company to address misinformation without making the correction a marketing communication.
Several types of activity can appear on the same platform. A company may make a product claim, provide risk information with that claim, or respond to a particular false statement. The content of the message and the company’s role in creating it determine which issue is involved.
Different expectations for online marketing
These principles apply most directly to promotional communications for drugs regulated by FDA. They do not cover much of the marketing copy on telehealth weight-loss sites, because compounded preparations are advertised under a different set of expectations, as described in FDA information on human drug compounding. That difference helps explain why claims about these products may vary widely between sites.
For someone comparing an online offer, the distinction may not be clear from the format alone. A short promotional message may be expected to place a product claim and risk information in the same communication. Marketing for a compounded preparation may be subject to different expectations. The guide to compounded GLP-1 medication explains what those preparations are and are not. Similar claims may not fall under the same promotional framework in every setting.
A review of an online offer therefore requires more than a reading of the benefit statement. The product category affects the expectations that apply, as do the source of the claim and the type of communication. These differences determine what a company is expected to disclose and how it may present a claim.
The guidance’s practical limit
The draft guidance applied content-based promotion rules to formats in which a complete communication was difficult to provide. It did not resolve the conflict between concise promotion and full risk disclosure. It also did not make every statement by an independent user a communication from the company.
The limits on corrections were similarly clear. A company could address specific misinformation, but the response had to remain truthful and non-promotional. It had to stay confined to the misinformation and clearly identify the company as the source. Those conditions maintained a distinction between correcting a claim and using a correction to create a new marketing message.
That distinction is central to the policy. Platforms may change, but the medium remains secondary to the message. The relevant questions are whether the company made a product claim, included risk information with it, or gave a narrow and transparent response to a specific falsehood. Those distinctions determine how responsibility attaches to a communication and when promotional oversight applies.